HC Wainwright Issues Optimistic Outlook for Ardelyx Earnings

Key Points

• HC Wainwright has increased its Q3 2025 earnings estimates for Ardelyx, projecting earnings of ($0.07) per share, an improvement from the previous estimate of ($0.08).
• Analyst ratings for Ardelyx are mixed, with eight "buy" ratings and varying target prices ranging from $9.00 to $14.00.
• Ardelyx reported $97.66 million in revenue for the last quarter, exceeding analyst expectations and representing a 23.0% year-over-year growth.

Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - HC Wainwright lifted their Q3 2025 EPS estimates for Ardelyx in a research report issued on Tuesday, August 5th. HC Wainwright analyst M. Caufield now anticipates that the biopharmaceutical company will earn ($0.07) per share for the quarter, up from their previous estimate of ($0.08). HC Wainwright has a "Buy" rating and a $10.00 price target on the stock. The consensus estimate for Ardelyx's current full-year earnings is ($0.18) per share. HC Wainwright also issued estimates for Ardelyx's Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.38) EPS and FY2026 earnings at ($0.17) EPS.

Ardelyx (NASDAQ:ARDX - Get Free Report) last issued its earnings results on Monday, August 4th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.13) by $0.05. The firm had revenue of $97.66 million during the quarter, compared to analyst estimates of $82.69 million. Ardelyx had a negative net margin of 14.60% and a negative return on equity of 36.57%. The company's quarterly revenue was up 23.0% on a year-over-year basis. During the same quarter last year, the business earned ($0.07) earnings per share.

A number of other equities analysts have also weighed in on ARDX. Piper Sandler increased their target price on shares of Ardelyx from $8.00 to $9.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Wedbush reissued an "outperform" rating and issued a $14.00 price target (up from $13.00) on shares of Ardelyx in a report on Tuesday, August 5th. UBS Group set a $12.00 price target on shares of Ardelyx in a report on Tuesday, August 5th. Wall Street Zen raised shares of Ardelyx from a "sell" rating to a "hold" rating in a report on Saturday. Finally, Raymond James Financial reissued an "outperform" rating and issued a $12.00 price target (up from $11.00) on shares of Ardelyx in a report on Tuesday, August 5th. Two research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Ardelyx currently has an average rating of "Moderate Buy" and a consensus target price of $11.50.

Ardelyx Stock Performance

NASDAQ:ARDX traded up $0.02 on Thursday, reaching $5.23. 1,939,618 shares of the company's stock were exchanged, compared to its average volume of 4,803,973. The company has a debt-to-equity ratio of 1.44, a current ratio of 4.30 and a quick ratio of 4.03. The firm has a market cap of $1.26 billion, a price-to-earnings ratio of -22.72 and a beta of 0.68. Ardelyx has a 52 week low of $3.21 and a 52 week high of $7.18. The stock has a fifty day simple moving average of $4.16 and a 200-day simple moving average of $4.63.

Hedge Funds Weigh In On Ardelyx

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Intech Investment Management LLC lifted its position in Ardelyx by 14.5% during the second quarter. Intech Investment Management LLC now owns 166,529 shares of the biopharmaceutical company's stock valued at $653,000 after buying an additional 21,028 shares during the period. Savant Capital LLC lifted its position in Ardelyx by 7.1% during the second quarter. Savant Capital LLC now owns 39,386 shares of the biopharmaceutical company's stock valued at $154,000 after buying an additional 2,610 shares during the period. Y Intercept Hong Kong Ltd purchased a new position in Ardelyx during the second quarter valued at $204,000. Brighton Jones LLC purchased a new position in Ardelyx during the second quarter valued at $40,000. Finally, Crux Wealth Advisors lifted its position in Ardelyx by 17.7% during the second quarter. Crux Wealth Advisors now owns 27,393 shares of the biopharmaceutical company's stock valued at $107,000 after buying an additional 4,120 shares during the period. Hedge funds and other institutional investors own 58.92% of the company's stock.

Insiders Place Their Bets

In related news, Director David M. Mott purchased 200,000 shares of the business's stock in a transaction that occurred on Monday, June 16th. The shares were acquired at an average price of $3.63 per share, for a total transaction of $726,000.00. Following the completion of the acquisition, the director directly owned 2,896,871 shares in the company, valued at approximately $10,515,641.73. The trade was a 7.42% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Mike Kelliher sold 14,522 shares of Ardelyx stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $4.08, for a total transaction of $59,249.76. Following the completion of the sale, the insider owned 282,158 shares in the company, valued at approximately $1,151,204.64. This trade represents a 4.89% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have purchased 500,000 shares of company stock valued at $1,793,000 and have sold 83,477 shares valued at $340,586. 4.80% of the stock is currently owned by insiders.

Ardelyx Company Profile

Ardelyx, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation.